Elizabeth Taras

641 total citations
15 papers, 539 citations indexed

About

Elizabeth Taras is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Elizabeth Taras has authored 15 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 10 papers in Immunology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Elizabeth Taras's work include CAR-T cell therapy research (6 papers), Immune Cell Function and Interaction (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Elizabeth Taras is often cited by papers focused on CAR-T cell therapy research (6 papers), Immune Cell Function and Interaction (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Elizabeth Taras collaborates with scholars based in United States, Germany and Sweden. Elizabeth Taras's co-authors include Daniel A. Vallera, Angela Panoskaltsis‐Mortari, Joerg Uwe Schmohl, Bruce R. Blazar, Martin Felices, Jonathan S. Serody, Andrew Price, Chris Lees, D.A. Todhunter and Hua Chen and has published in prestigious journals such as Blood, The Journal of Immunology and Molecular Therapy.

In The Last Decade

Elizabeth Taras

14 papers receiving 528 citations

Peers

Countries citing papers authored by Elizabeth Taras

Since Specialization

Citations

This map shows the geographic impact of Elizabeth Taras's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Taras with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Taras more than expected).

Fields of papers citing papers by Elizabeth Taras

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Taras. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Taras. The network helps show where Elizabeth Taras may publish in the future.

Co-authorship network of co-authors of Elizabeth Taras

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Taras. A scholar is included among the top collaborators of Elizabeth Taras based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Taras. Elizabeth Taras is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Impact of repeated cycles of EGF bispecific angiotoxin (eBAT) administered at a reduced interval from doxorubicin chemotherapy in dogs with splenic haemangiosarcoma 2020 ·Veterinary and Comparative Oncology ·Antonella Borgatti, Ann Fieberg, (unknown), (unknown), Elizabeth Taras, D.A. Todhunter, (unknown), (unknown), Daniel A. Vallera, Joseph S. Koopmeiners, Jaime F. Modiano	4
2	Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin 2018 ·Clinical Pharmacology Advances and Applications ·(unknown), D.A. Todhunter, Elizabeth Taras, Daniel A. Vallera, Antonella Borgatti	14
3	Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies 2018 ·Toxins ·Joerg Uwe Schmohl, D.A. Todhunter, Elizabeth Taras, Veronika Bachanová, Daniel A. Vallera	20
4	Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors 2017 ·Oncotarget ·(unknown), Hongbo Wang, Elizabeth Taras, (unknown), (unknown), Todd E. DeFor, Antonella Borgatti, Daniel A. Vallera, Michael R. Verneris	20
5	Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker 2016 ·Molecular Therapy ·Joerg Uwe Schmohl, Martin Felices, Elizabeth Taras, (unknown), Daniel A. Vallera	83
6	CD16-IL15-CD33 Trispecific Killer Engager (TriKE) induces NK cell expansion, persistence, and myeloid blast antigen specific killing. 2016 ·The Journal of Immunology ·Martin Felices, Daniel A. Vallera, Ron McElmurry, Alexander J. Lenvik, Sami Chu, D.A. Todhunter, Elizabeth Taras, Jakub Tolar, Bruce R. Blazar, Jeffrey S. Miller	0
7	CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics 2016 ·Blood ·Martin Felices, Dhifaf Sarhan, (unknown), Karolin Guldevall, Ron McElmurry, Alexander J. Lenvik, Sami Chu, Jakub Tolar, Elizabeth Taras, Stephen R. Spellman, Erica D. Warlick, Michael R. Verneris, Sarah Cooley, Daniel J. Weisdorf, Bruce R. Blazar, Björn Önfelt, D. A. Vallera, Jeffrey S. Miller	8
8	Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker 2016 ·Oncotarget ·Joerg Uwe Schmohl, Martin Felices, D.A. Todhunter, Elizabeth Taras, Jeffrey S. Miller, Daniel A. Vallera	55
9	Trispecific Killer Engagers (TriKEs) that contain IL-15 to make NK cells antigen specific and to sustain their persistence and expansion 2015 ·Blood ·Jeffrey S. Miller, (unknown), Ron McElmurry, (unknown), Xianzheng Zhou, Jakub Tolar, Joerg Uwe Schmohl, Angela Panoskaltsis‐Mortari, Bin Zhang, Elizabeth Taras, Michael R. Verneris, Sarah Cooley, Daniel J. Weisdorf, Bruce R. Blazar, D. A. Vallera	10
10	Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression 2013 ·Gynecologic Oncology ·Amy P.N. Skubitz, Elizabeth Taras, Kristin L.M. Boylan, Nate N. Waldron, Seunguk Oh, Angela Panoskaltsis‐Mortari, Daniel A. Vallera	83
11	Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy 2009 ·Leukemia Research ·Daniel A. Vallera, Hua Chen, (unknown), Angela Panoskaltsis‐Mortari, Elizabeth Taras	68
12	Radiotherapy of CD45-Expressing Daudi Tumors in Nude Mice with Yttrium-90-Labeled, PEGylated Anti-CD45 Antibody 2007 ·Cancer Biotherapy and Radiopharmaceuticals ·Daniel A. Vallera, (unknown), Elizabeth Taras, Martin W. Brechbiel, (unknown), Angela Panoskaltsis‐Mortari, Linda J. Burns	6
13	Post-BMT lung injury occurs independently of the expression of CCL2 or its receptor, CCR2, on host cells 2004 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Angela Panoskaltsis‐Mortari, (unknown), Elizabeth Taras, O. Douglas Wangensteen, Israel Charo, Barrett J. Rollins, Bruce R. Blazar	12
14	In vivo imaging of graft-versus-host-disease in mice 2004 ·Blood ·Angela Panoskaltsis‐Mortari, Andrew Price, (unknown), Elizabeth Taras, Chris Lees, Jonathan S. Serody, Bruce R. Blazar	124
15	Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1α (CCL3) after allogeneic BMT in mice 2003 ·Blood ·Angela Panoskaltsis‐Mortari, (unknown), Elizabeth Taras, O. Douglas Wangensteen, Jonathan S. Serody, Bruce R. Blazar	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact